Hope thrives in the desert
Home > Science & Research > Clinical Trials

Available Clinical Trials

The Nevada Cancer Institute offers many diverse options for the treatment of cancer. For more detailed description of each trial, click on the type of cancer to open a PDF document with the details, including criteria for enrollment, for selected study.

» Phase I
» Genitourinary
» Lung
» Gastrointestinal
» Hematology
» Skin/Melanoma
» Return to Clinical Trials main

Phase 1

Advanced CancerPhase IAlina
(702) 822-5346		A Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid In Combination with Pemetrexed & Cisplatin In Patients with Advanced Cancer
Advanced Non-Hematological MalignanciesPhase IDianna
(702) 822-5483		A randomized crossover oral bioavailability study comparing the pharmacokinetics and pharmacodynamics of Picoplatin administered orally with Picoplatin administered intravenously in subjects with advanced non-hematological malignancies
Advanced Solid TumorsPhase IDonna
(702) 822-5173		A Phase I Study of Concurrent Sorafenib (BAY 43-9006) and Palliative Radiation Therapy in Adult Patients with Advanced Solid Tumors
Advanced Solid TumorsPhase IMontessa
(702) 822-5282		Multiple Ascending Dose (MAD) Phase I Study of RO4612910 Administered Orally on a Daily x 14 Consecutive Days every 3 Week Schedule in Patients with A Phase I Study of RO4612910 Administered Orally QD x Days Q 3 Wks Schedule In Pts With Adv Solid Tumors
Advanced Solid TumorsPhase IMontessa
(702) 822-5282		Phase I clinical and Pharmacokinetic study of CBP501 and cicplatin every 3 weeks in patients with advanced refractory solid tumors
Advanced Solid Tumors & Non-Hodgkin's LymphomaPhase IDonna
(702) 822-5173		A Phase IA, two-arm, multicenter, dose-escalating study of LBH589 administered intravenously on two dose schedules in adult patients with advanced solid tumors and non-Hodgkin's lymphoma
Solid MalignanciesPhase IKaren
(702) 822-5367		A Phase I Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies
Advanced CancerPhase I/IIAlina
(702) 822-5346		A Continuation Clinical Trial of Oral L-001079038 in Advanced Cancers
Advanced CancerPhase I/IIAlina
(702) 822-5346		A Phase I/II , multi-center, randomized dose escalation of oral AEE788 on intermittent dosing schedules in adult patients with advanced cancer
Advanced Solid MalignanciesPhase I/IIAlina
(702) 822-5346		A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in patients with either HER2 positive or ER positive locally advanced or metastatic breast cancer
Advanced Solid MalignanciesPhase I/IIMontessa
(702) 822-5282		A Phase I/II, multi-center, open label study of BEZ235, administered orally on a continous daily dosing schedule in adult patient with advanced solid malignancies including patients with advanced breast cancer
Advanced Solid TumorsPhase I/IIAlina
(702) 822-5346		An open-label, multi-center, 2-arm Phase I/II trial of LBY135 alone and in combination with capecitabine in advanced solid tumors
top ^

Gastrointestinal

Metastatic Colorectal AdenocarcinomaPhase IDonna
(702) 822-5173		An open-label, multicenter Phase 1 study investigating the combination of RAD001, cetuximab and irinotecan as second-line therapy after FOLFOX (or XELOX) plus bevacizumab (if given as part of local standard practice) in patients with metastatic colorectal adenocarcinoma
Metastatic Colorectal CancerPhase I/IIKaren
(702) 822-5267		A randomized Phase II study of the anti-angiogenesis agent AG-013736 in combinations with chemotherapy and Bevacizumab in patients with metastatic colorectal cancer preceded by a Phase I portion
Metastatic Colorectal AdenocarcinomaPhase IICarol
(702) 822-5449		A Phase II study of RAD001 in patients with metastatic colorectal adenocarcinoma whose cancer has progressed despite prior therapy with an anti-EGFR antibody (if appropriate), bevacizumab, fluoropyrimidine, oxaliplatin, and irinotecan-based regimens
top ^

Genitourinary

Prostate CancerPhase IDeralyn
(702) 822-5116		Nevada Cancer Institutes study of Biological Markers in Prostate Cancer
Prostate CancerPhase I/IIDonna
(702) 822-5173		A phase IA/IB/II, two arm, multi-center, open-label, dose escalation study of oral LBH589 alone and in combination with IV docetaxel (Taxotere® ) and oral Prednisone® in hormone refractory prostate cancer (HRPC)
Metastatic Kidney CarcinomaPhase IIChristine
(702) 822-5456		A phase II study to compare the safety and efficacy of RAD001 plus Best Supportive Care (BSC) versus BSC plus Placebo in patients with metastatic carcinoma of the kidney which has progressed on VEGF receptor tyrosine kinase inhibitor therapy
Prostate CancerPhase IIChristine
(702) 822-5456		A Phase II Trial of Oral Enzastaurin in Prostate Cancer Patients Who Have Rising PSA (1) During Hormonal Manipulation, or (2) After First-Line Cytotoxic Chemotherapy
Advanced Transitional Cell Carcinoma of the UrotheliumPhase II/IIICarol
(702) 822-5449		A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced TCC of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients who are Ineligible to Receive Cisplatin-Based Therapy (VINCENT)
Clear Celll Renal Cell CarcinomaPhase IIICarol
(702) 822-5449		A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with clear cell RCC and high risk of recurrence
Metastatic Renal Cell CancerPhase IIIChristine
(702) 822-5456		A randomized Phase III study of the efficacy and safety of Sunitinib Malate alone or in combination with Interferon Alfa-2B as first-line therapy for metastatic renal cell cancer (Renal Effect Trial)
Prostate CancerPhase IIICarol
(702) 822-5449		A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy(ELIGARD) in Combination with TAXOTERE Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy in Pts with Prostate Cancer
Prostate CancerPhase IIICarol
(702) 822-5449		A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT by Chemotherapy With Docetaxel and Prednisone For Localized, High-Risk Prostate Cancer
Prostate CancerPhase IIIChristine
(702) 822-5456		A Phase III, Randomized, Open-Label Study Evaluating DN-101 in Combination with Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)
top ^

Hematology

LymphomaNo PhaseChristine
(702) 822-5456		An Open Label Dose and Schedule Finding Trial to Evaulate the Safety and Efficacy of AMG 531 for Treatment of Severe Thrombocytopenia Due to Multi-Cycle Chemotherapy in Adult Subjects with Lymphoma
Non-Hodgkin's LymphomaPhase I/IIChristine
(702) 822-5456		A Phase 1/2 Study of CMC-544 Administered in Combination With Rituximab in Subjects With Follicular or Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Non-Hodgkin's LymphomaPhase I/IIChristine
(702) 822-5456		Phase 1/2 Dose-Escalation Study Of AME 133v (LY2469298), Administered Intravenously in Four Weekly Doses, in Subjects With CD20+ Follicular Relapsed or Refractory Non-Hodgkin’s Lymphoma
Hodgkin's DiseasePhase IIKaren
(702) 822-5367		Phase II Study of MDX-060 in Combination with Gemcitabine, MDX-060 in Combination with Dexamethasone, and Gemcitabine Monotherapy in Patients with Relapsed or Refractory Hodgkin’s Disease
LymphomaPhase IICarol
(702) 822-5449		A Multi-center Phase 2 Open-label Study of (RS)-10-Propargyl-10-Deazaaminopterin (pralatrexate) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
LymphomaPhase IICarol
(702) 822-5449		A Phase II, Randomized, Multicenter, Comparative Trial of CHOP-R and CPOP-R in Elderly Patients with Diffuse Large-B-cell Lymphoma
Chronic Myeloid LeukemiaPhase IIIChristine
(702) 822-5456		An Open-Label Randomized Phase III Study of Dasatinib vs. Standard-Dose (400 mg) Imatinib Mesylate in the Treatment of Subjects with Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia who have had a Suboptimal Response
Chronic Myeloid LeukemiaPhase IIICarol
(702) 822-5449		An open-label, multi-center, expanded access study of oral AMN 107 in adult patients with Imatinib (Glivec®/Gleevec®) - resistant or - intolerant chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase
top ^

Lung

Non-Small Cell Lung CancerPhase ILeslie
(702) 822-5103		A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG01 in Combination with Erlotinib in Non-Small Cell Lung Cancer Patients
Non-Small-Cell Lung CancerPhase I/IIKaren
(702) 822-5367		A Phase I/II Clinical Trial of Oral Vorinostat (MK-0683) in Combination With Erlotinib in Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer
Non-Small-Cell Lung CancerPhase IIICarol
(702) 822-5449		A Phase I/II Study of Pemetrexed (Alimta) plus Carboplatin, or Pemetrexed plus Cisplatin with Concurrent Radiation Therapy folled by Every 21-day Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage III A/B Non Small Cell Lung Cancer
Non-Small-Cell Lung CancerPhase IIIKaren
(702) 822-5367		A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer
top ^

Skin/Melanoma

MelanomaNo PhaseSusan
(702) 822-5446		The Early Detection of Melanoma and Other Cancers in Residents of Nevada
Advanced MelanomaPhase IIIChristine
(702) 822-5456		A Phase III, open label, randomized, comparative study of Ticilimumab and either Dacarbazine or Temozolomide in patients with advanced melanoma
top ^
Contact Us
Please contact us with any questions or comments.
(702) 822-LIFE

(866) 621-NVCI

FightHere.org

Latest News

Nevada Cancer Institute Announces Sun Safety Art Poster Contest Winner (Our Lady of Las Vegas School)

Read more

Nevada Cancer Institute Celebrates LIVESTRONG Day!

Read more

Lower-Cost Mammograms Available to Nevada Women

Read more

Maps & Directions

To visit our state-of-the-art, flagship facility click here.

Outreach & Education offices:

Las Vegas | Sparks | Elko | Fallon
©2008 Nevada Cancer Institute. All rights reserved. One Breakthrough Way. Las Vegas, NV 89135 | (702) 822-LIFE
Contact Us | Notice of Privacy Practices | Patient Rights | Site Map | Home